NCT06623136招募中2 期
An Open-label, Multicenter, Single-arm Phase 2 Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 9
- 主要终点
- Objective Response Rate (ORR) assessed by IRC
研究概览
简要总结
The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Having sufficient understanding of this study and being willing to sign the informed consent form (ICF).
- •Males or females, age 18-75 years at the time of signing the informed consent form.
- •Histologically or cytologically confirmed, unresectable locally advanced and metastatic non-small cell lung cancer not suitable for radical concurrent chemoradiotherapy.
- •Without known EGFR mutation/ALK fusion/ROS1 fusion gene.
- •Previous failed concurrent or sequential treatment with systemic platinum-containing chemotherapy and PD-1/PD-L1 inhibitor therapy for NSCLC that cannot be radically resected or not suitable for radical concurrent radio chemotherapy.
- •Five consecutive unstained slides from formalin-fixed paraffin-embedded (FFPE) tumor tissue (archived tumor tissue up to 5 years or freshly biopsied tumor tissue) sources are available for PD-L1 testing in the central laboratory.
- •PD-L1 TPS ≥50% by 22C3 antibody IHC assay in the central laboratory.
- •At least one measurable lesion (in accordance with RECIST v1.1).
- •Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or
- •Estimated life expectancy of at least 3 months.
- •Adequate hematologic, hepatic, renal and coagulation function as defined per protocol.
- •Male and female subjects of childbearing potential must be willing to be completely abstinent or to use a highly effective method of contraception (i.e., a failure rate of less than 1%) from the time of signing the informed consent form until 3 months after the last dose of study drug.
排除标准
- •Any prior therapy targeting OX
- •Receipt of any other investigational drug or device intervention within 28 days prior to the first dose of the study drug.
- •Receipt of anticancer Chinese herbal therapy within 14 days prior to the first dose of the study drug.
- •Receipt of radiotherapy within 14 days prior to the first dose of the study drug.
- •Receipt of any other anti-cancer drug(s) including chemotherapy, targeted therapy, immunotherapy, biotherapy, etc., within 28 days or 5 half-lives prior to the first dose of the study drug.
- •Prior allogeneic or autologous bone marrow transplant or solid organ transplant.
- •The toxicity from prior anti-cancer therapies has not resolved to ≤ Grade 1 per NCI-CTCAE v5.
- •Certain exceptions as defined in protocol apply.
- •Systemic glucocorticoids (e.g., >10 mg/day of prednisone or equivalent doses of similar drugs) or other immunosuppressive agents were required for systemic treatment within 14 days prior to the first dose of the study drug or during the study period.
- •Major surgery within 28 days prior to the first dose of the study drug.
- •Receipt of live viral vaccine treatment within 28 days prior to the first dose of the study drug.
- •Known allergy to CHO-produced antibodies, which in the opinion of the Investigator suggests an increased potential for hypersensitivity to ES
- •Subjects with an allergic reaction to the active ingredients ofToripalimab or any of the excipients.
- •Known allergy to the pre-medication prescribed in the protocol and unable to receive pre-medication.
- •History of invasive malignant tumors other than the study disease within the past two years. Some exceptions as defined per protocol apply.
- •History of immune-related adverse events (irAEs) of Grade ≥3 or those that led to discontinuation of treatment. Some exceptions as defined per protocol apply.
- •Active autoimmune disease or a known history of autoimmune disease requiring systemic corticosteroid or immunosuppressive treatment.
- •Active interstitial lung disease (ILD) or pneumonia; or a history of ILD or (non-infectious) pneumonia requiring corticosteroid or other immunosuppressive treatment.
- •Central Nervous System (CNS) metastases.
- •Active infection requiring systemic treatment; Human Immunodeficiency Virus (HIV) infection (HIV antibody positive); Hepatitis B Virus (HBV) infection (HBsAg positive) or Hepatitis C Virus (HCV) infection (HCV antibody positive). Some exceptions as defined per protocol apply.
- •Cirrhosis, alcoholic hepatitis, drug-induced hepatitis, non-alcoholic steatohepatitis, and hereditary liver diseases.
- •History or evidence of cardiovascular abnormalities.
- •Pregnant or breastfeeding women.
- •Any known, documented, or suspected history of substance abuse that would preclude subject from participation, certain exceptions as defined in protocol apply.
- •Any other disease or clinically significant abnormal laboratory parameters that investigator considers may compromise subject safety or study integrity, interfere with subject participation in the trial, or affect the study objectives, including serious medical or psychiatric illness/condition.
- •Personnel involved in the design and/or implementation of the study (applicable to sponsor/CRO personnel and site personnel).
- •Subjects are unable to comply with the study procedures, restrictions and requirements, in the opinion of Investigator.
研究组 & 干预措施
ES102 in combination with Toripalimab
Experimental
干预措施: ES102 (Drug)
ES102 in combination with Toripalimab
Experimental
干预措施: Toripalimab (Drug)
结局指标
主要结局
Objective Response Rate (ORR) assessed by IRC
时间窗: 1-2 years
Proportion of subjects achieving complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Independent Review Committee (IRC).
次要结局
- ORR assessed by investigators(1-2 years)
- Disease control rate (DCR)(1-2 years)
- Duration of response (DOR)(1-2 years)
- Progression-free survival (PFS)(1-2 years)
- Overall survival (OS)(1-2 years)
- Adverse events (AE)(1-2 years)
- Plasma concentration(1-2 years)
- Immunogenicity Toripalimab(1-2 years)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
1 期
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaMultiple Myeloma in RelapseNCT03136653Molecular Partners AG33
招募中
2 期
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TBNCT02354014Janssen Research & Development, LLC60
已完成
2 期
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic MelanomaMelanomaNCT05419388Hoffmann-La Roche93
招募中
2 期
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric CancerNCT06219941AstraZeneca226
进行中（未招募）
2 期
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNCT06450639Hoffmann-La Roche30